Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25271037 | 1.00 | MEN1 (0.51) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL30455736 | 1.00 | MEN1 (0.51) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL25227044 | 1.00 | MEN1 (0.51) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL25277616 | 0.94 | MEN1 (0.45) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL31501637 | 0.94 | MEN1 (0.45) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL25277615 | 0.94 | MEN1 (0.45) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL30405361 | 0.94 | MEN1 (0.45) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL31501678 | 0.94 | MEN1 (0.51) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL31501657 | 0.89 | MEN1 (0.45) | MEN1KMT2AKCNH2CNR1DRD2 | |
| SCHEMBL31501631 | 0.88 | MEN1 (0.43) | MEN1KMT2AKCNH2CNR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | claimed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | MEN1 2/4885KMT2A 8/4885KCNH2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.